Equine encephalitis - Pipeline Insight, 2024

This “Equine encephalitis - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Equine encephalitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Equine encephalitis Understanding

Equine encephalitis: Overview

Western, Eastern and Venezuelan equine encephalitis viruses vary in infection rates and severity of disease, although all three pathogens are associated with risks of flu-like symptoms, potential central nervous disorders, and death. The virus is spread by mosquitos to humans and can result in the rare condition of encephalitis in about 5% of the people that become infected. In the United States, an increase in cases of Eastern equine encephalitis, known also as Triple E, has been reported over the past years, and in 2019 almost 40 cases, including 15 deaths were reported by the CDC in what is the largest ever recorded outbreak of Triple E. There are currently no approved vaccines against any of the equine encephalitis viruses.

Equine encephalitis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Equine encephalitis pipeline landscape is provided which includes the disease overview and Equine encephalitis treatment guidelines. The assessment part of the report embraces, in depth Equine encephalitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Equine encephalitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Equine encephalitis R&D. The therapies under development are focused on novel approaches to treat/improve Equine encephalitis.

Equine encephalitis Emerging Drugs Chapters

This segment of the Equine encephalitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Equine encephalitis Emerging Drugs

MVA-BN® WEV: Bavarian NordicUnder a contract with the U.S. Government, awarded in 2018, Bavarian Nordic has developed MVA-BN WEV, a vaccine against equine encephalitis virus, an emerging mosquito-borne virus which can result in the rare condition of encephalitis and death. In June 2020, topline results from the first-in-human trial of MVA-BN WEV were reported. Data from the study showed that the vaccine was well tolerated and immunogenic across all dose groups. Neutralizing antibody responses were observed in all dose groups, with peak levels reached after the second vaccination. These clinically meaningful Phase 1 data warrant further clinical investigation, and Bavarian Nordic is seeking additional funding for the further clinical advancement of the vaccine candidate.

Molnupiravir: Ridgeback Biotherapeutics/MerckMolnupiravir is a direct-acting oral, broad-spectrum antiviral agent in clinical development as a treatment for COVID-19. Ridgeback has completed Phase 1 and Phase 2 studies. The program has advanced into Phase 3 development as a therapeutic for COVID-19. Administered as an oral capsule, Molnupiravir has also shown activity in animal models of Ebola, Equine Encephalitis (VEEV and EEEV), Influenza (seasonal, pandemic and avian), and Respiratory Syncytial Virus. Molnupiravir is being developed under a collaboration agreement with Merck (known as MSD outside the U.S. and Canada).

Equine encephalitis: Therapeutic Assessment

This segment of the report provides insights about the different Equine encephalitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Equine encephalitis

There are approx. 5+ key companies which are developing the therapies for Equine encephalitis. The companies which have their Equine encephalitis drug candidates in the most advanced stage, i.e. phase I include, Bavarian Nordic.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Equine encephalitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Equine encephalitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Equine encephalitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Equine encephalitis drugs.

Equine encephalitis Report Insights

• Equine encephalitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Equine encephalitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Equine encephalitis drugs?
• How many Equine encephalitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Equine encephalitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Equine encephalitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Equine encephalitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Bavarian Nordic
• Merck & Co
• Ridgeback Biotherapeutics
• AlphaVax
• Mapp Biopharmaceutical

Key Products

• Molnupiravir
• MVA-BN® WEV

Research programme: biodefence vaccines- Research programme: Venezuelan equine encephalomyelitis anti-infective antibodies


This product will be delivered within 1-3 business days.